Abstract
Recent advancements in mammalian genome editing technologies have demonstrated precise genetic manipulations at the chromosomal level at efficiencies relevant for disease therapy. In fact, zinc-finger nucleases (ZFNs) that induce deletions in the HIV CCR5 receptor in patient T cells ex vivo have demonstrated promise upon treated cell infusion in the clinic. In these applications, adenoviral delivery vectors were employed however; there is growing popularity for the use of adeno-associated virus (AAV) gene delivery which has been used in over 100 clinical trials without any vector-related toxicity. This review chapter summarizes the development of AAV for clinical gene therapy, the early observations of AAV gene targeting, and the current status of AAV vectors for gene editing via site specific DNA double strand break repair. In addition, the remaining obstacles towards the combination of AAV vectorology and site-specific endonucleases for genetic engineering are discussed.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Atchison RW, Casto BC, Hammon WM. Adenovirus-associated defective virus particles. Science. 1965;149(3685):754–6.
Fields BN, Knipe DM, Howley PM. Ovid technologies Inc. Fields’ virology. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2007. Available from: http://eresources.lib.unc.edu/external_db/external_database_auth.html?A=P%7CF=N%7CID=162631%7CREL=HSL%7CSO=HSL%7CURL=http://libproxy.lib.unc.edu/login?url=http://gateway.ovid.com/ovidweb.cgi?T=JS&NEWS=N&PAGE=booktext&D=books&AN=00139921/5th_Edition/.
Berns KI, Pinkerton TC, Thomas GF, Hoggan MD. Detection of adeno-associated virus (AAV)-specific nucleotide sequences in DNA isolated from latently infected Detroit 6 cells. Virology. 1975;68(2):556–60.
Xiao X, Xiao W, Li J, Samulski RJ. A novel 165-base-pair terminal repeat sequence is the sole cis requirement for the adeno-associated virus life cycle. J Virol. 1997;71(2):941–8.
King JA, Dubielzig R, Grimm D, Kleinschmidt JA. DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into preformed capsids. EMBO J. 2001;20(12):3282–91.
Kyostio SR, Owens RA, Weitzman MD, Antoni BA, Chejanovsky N, Carter BJ. Analysis of adeno-associated virus (AAV) wild-type and mutant Rep proteins for their abilities to negatively regulate AAV p5 and p19 mRNA levels. J Virol. 1994;68(5):2947–57.
Sonntag F, Schmidt K. Kleinschmidt JrA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl Acad Sci. 2010;107(22):10220–5.
Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X, et al. Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol. 2004;78(12):6381–8.
Ellis B, Hirsch M, Barker J, Connelly J, Steininger R, Porteus M. A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype. Virol J. 2013;10(1):74. doi:10.1186/1743-422X-10-74.
Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther. 2008;16(6):1073–80.
Grieger JC, Choi VW, Samulski RJ. Production and characterization of adeno-associated viral vectors. Nat Protoc. 2006;1(3):1412–28. PubMed Epub 2007/04/05. eng.
Asokan A, Schaffer DV, Samulski RJ. The AAV vector toolkit: poised at the clinical crossroads. Mol Ther. 2012;20(4):699–708. PubMed Epub 2012/01/26. eng.
Bartlett JS, Wilcher R, Samulski RJ. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J Virol. 2000;74(6):2777–85.
Xiao PJ, Samulski RJ. Cytoplasmic trafficking, endosomal escape, and perinuclear accumulation of adeno-associated virus type 2 particles are facilitated by microtubule network. J Virol. 2012;86(19):10462–73. PubMed Epub 2012/07/20. eng.
Popa-Wagner R, Porwal M, Kann M, Reuss M, Weimer M, Florin L, et al. Impact of VP1-specific protein sequence motifs on adeno-associated virus type 2 intracellular trafficking and nuclear entry. J Virol. 2012;86(17):9163–74.
Rabinowitz JE, Samulski RJ. Building a better vector: the manipulation of AAV virions. Virology. 2000;278(2):301–8.
Johnson JS, Samulski RJ. Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus. J Virol. 2009;83(6):2632–44. PubMed Pubmed Central PMCID: 2648275, Epub 2008/12/26. eng.
Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol. 1996;70(5):3227–34.
Beaton A, Palumbo P, Berns KI. Expression from the adeno-associated virus p5 and p19 promoters is negatively regulated in trans by the rep protein. J Virol. 1989;63(10):4450–4. PubMed Epub 1989/10/01. eng.
Miao CH, Snyder RO, Schowalter DB, Patijn GA, Donahue B, Winther B, et al. The kinetics of rAAV integration in the liver. Nat Genet. 1998;19(1):13–5. PubMed Epub 1998/05/20. eng.
Cheung AK, Hoggan MD, Hauswirth WW, Berns KI. Integration of the adeno-associated virus genome into cellular DNA in latently infected human Detroit 6 cells. J Virol. 1980;33(2):739–48.
Hirsch ML, Storici F, Li C, Choi VW, Samulski RJ. AAV recombineering with single strand oligonucleotides. PLoS One. 2009;4(11), e7705. PubMed Pubmed Central PMCID: 2765622, Epub 2009/11/06. eng.
Kotin RM, Siniscalco M, Samulski RJ, Zhu XD, Hunter L, Laughlin CA, et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A. 1990;87(6):2211–5.
Samulski RJ, Zhu X, Xiao X, Brook JD, Housman DE, Epstein N, et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J. 1991;10(12):3941–50. PubMed Epub 1991/12/01. eng.
Deyle DR, Russell DW. Adeno-associated virus vector integration. Curr Opin Mol Ther. 2009;11(4):442–7. PubMed Epub 2009/08/04. eng.
McCarty DM, Young Jr SM, Samulski RJ. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet. 2004;38:819–45. PubMed Epub 2004/12/01. eng.
Rosas LE, Grieves JL, Zaraspe K, La Perle KMD, Fu H, McCarty DM. Patterns of scAAV vector insertion associated with oncogenic events in a mouse model for genotoxicity. Mol Ther. 2012;20(11):2098–110.
Miller DG, Trobridge GD, Petek LM, Jacobs MA, Kaul R, Russell DW. Large-scale analysis of adeno-associated virus vector integration sites in normal human cells. J Virol. 2005;79(17):11434–42.
McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 2001;8(16):1248–54. PubMed Epub 2001/08/18. eng.
Wang Z, Ma HI, Li J, Sun L, Zhang J, Xiao X. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther. 2003;10(26):2105–11. PubMed Epub 2003/11/20. eng.
McCarty DM, Fu H, Monahan PE, Toulson CE, Naik P, Samulski RJ. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther. 2003;10(26):2112–8. PubMed Epub 2003/11/20. eng.
Hirsch ML, Green L, Porteus MH, Samulski RJ. Self-complementary AAV mediates gene targeting and enhances endonuclease delivery for double-strand break repair. Gene Ther. 2010;17(9):1175–80. PubMed Pubmed Central PMCID: 3152950, Epub 2010/05/14. eng.
Mueller C, Flotte TR. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther. 2008;15(11):858–63.
Podsakoff G, Wong KK, Chatterjee S. Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. J Virol. 1994;68(9):5656–66.
Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol. 1996;70(11):8098–108.
Rabinowitz JE, Bowles DE, Faust SM, Ledford JG, Cunningham SE, Samulski RJ. Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups. J Virol. 2004;78(9):4421–32. PubMed Epub 2004/04/14. eng.
Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X, et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol. 2002;76(2):791–801. PubMed Epub 2001/12/26. eng.
Ellis BL, Hirsch ML, Barker JC, Connelly JP, Steininger 3rd RJ, Porteus MH. A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype. Virol J. 2013;10:74. PubMed Pubmed Central PMCID: 3607841.
Mitchell AM, Nicolson SC, Warischalk JK, Samulski RJ. AAV’s anatomy: roadmap for optimizing vectors for translational success. Curr Gene Ther. 2010;10(5):319–40. PubMed Epub 2010/08/18. eng.
Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365(25):2357–65. PubMed Pubmed Central PMCID: 3265081, Epub 2011/12/14. eng.
Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006;12(3):342–7. PubMed Epub 2006/02/14. eng.
Gray SJ. Gene therapy and neurodevelopmental disorders. Neuropharmacology. 2013;68:136–42. PubMed Epub 2012/07/04. eng.
Zouein FA, Booz GW. AAV-mediated gene therapy for heart failure: enhancing contractility and calcium handling. F1000Prime Rep. 2013;5:27. PubMed Epub 2013/08/24. eng.
Gaudet D, Methot J, Kastelein J. Gene therapy for lipoprotein lipase deficiency. Curr Opin Lipidol. 2012;23(4):310–20. PubMed Epub 2012/06/14. eng.
Carpentier AC, Frisch F, Labbe SM, Gagnon R, de Wal J, Greentree S, et al. Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J Clin Endocrinol Metab. 2012;97(5):1635–44. PubMed Epub 2012/03/23. eng.
Gaudet D, Methot J, Dery S, Brisson D, Essiembre C, Tremblay G, et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther. 2013;20(4):361–9. PubMed Epub 2012/06/22. eng.
Stroes ES, Nierman MC, Meulenberg JJ, Franssen R, Twisk J, Henny CP, et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol. 2008;28(12):2303–4. PubMed Epub 2008/09/20. eng.
Ali RR, Reichel MB, Thrasher AJ, Levinsky RJ, Kinnon C, Kanuga N, et al. Gene transfer into the mouse retina mediated by an adeno-associated viral vector. Hum Mol Genet. 1996;5(5):591–4. PubMed Epub 1996/05/01. eng.
Barker SE, Broderick CA, Robbie SJ, Duran Y, Natkunarajah M, Buch P, et al. Subretinal delivery of adeno-associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent mice. J Gene Med. 2009;11(6):486–97.
Jacobson SG, Cideciyan AV, Ratnakaram R, Heon E, Schwartz SB, Roman AJ, et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol. 2012;130(1):9–24. PubMed Epub 2011/09/14. eng.
McClements ME, MacLaren RE. Gene therapy for retinal disease. Transl Res. 2013;161(4):241–54. PubMed Epub 2013/01/12. eng.
Testa F, Maguire AM, Rossi S, Pierce EA, Melillo P, Marshall K, et al. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology. 2013;120(6):1283–91. PubMed Pubmed Central PMCID: 3674112.
Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, et al. Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med. 2008;358(21):2231–9. PubMed Epub 2008/04/29. eng.
Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, Wang L, et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther. 2008;19(10):979–90. PubMed Epub 2008/09/09. eng.
Maguire AM, High KA, Auricchio A, Wright JF, Pierce EA, Testa F, et al. Age-dependent effects of RPE65 gene therapy for Leber’s congenital amaurosis: a phase 1 dose-escalation trial. Lancet. 2009;374(9701):1597–605. PubMed Epub 2009/10/27. eng.
Maguire AM, Simonelli F, Pierce EA, Pugh Jr EN, Mingozzi F, Bennicelli J, et al. Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med. 2008;358(21):2240–8. PubMed Epub 2008/04/29. eng.
Bennett J, Ashtari M, Wellman J, Marshall KA, Cyckowski LL, Chung DC, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med. 2012;4(120):120ra15.
Cai X, Conley SM, Naash MI. RPE65: role in the visual cycle, human retinal disease, and gene therapy. Ophthalmic Genet. 2009;30(2):57–62. PubMed Epub 2009/04/18. eng.
Russell DW, Hirata RK. Human gene targeting by viral vectors. Nat Genet. 1998;18(4):325–30. PubMed Pubmed Central PMCID: 3010411, Epub 1998/04/16. eng.
Russell DW, Hirata RK. Human gene targeting favors insertions over deletions. Hum Gene Ther. 2008;19(9):907–14. PubMed Pubmed Central PMCID: 2940567.
Hirata RK, Russell DW. Design and packaging of adeno-associated virus gene targeting vectors. J Virol. 2000;74(10):4612–20. PubMed Pubmed Central PMCID: 111981, Epub 2000/04/25. eng.
Russell DW, Miller AD, Alexander IE. Adeno-associated virus vectors preferentially transduce cells in S phase. Proc Natl Acad Sci U S A. 1994;91(19):8915–9. PubMed Pubmed Central PMCID: 44717.
Trobridge G, Hirata RK, Russell DW. Gene targeting by adeno-associated virus vectors is cell-cycle dependent. Hum Gene Ther. 2005;16(4):522–6. PubMed.
Liu X, Yan Z, Luo M, Zak R, Li Z, Driskell RR, et al. Targeted correction of single-base-pair mutations with adeno-associated virus vectors under nonselective conditions. J Virol. 2004;78(8):4165–75. PubMed Pubmed Central PMCID: 374254.
Cervelli T, Palacios JA, Zentilin L, Mano M, Schwartz RA, Weitzman MD, et al. Processing of recombinant AAV genomes occurs in specific nuclear structures that overlap with foci of DNA-damage-response proteins. J Cell Sci. 2008;121(Pt 3):349–57. PubMed.
Inagaki K, Ma C, Storm TA, Kay MA, Nakai H. The role of DNA-PKcs and artemis in opening viral DNA hairpin termini in various tissues in mice. J Virol. 2007;81(20):11304–21. PubMed Pubmed Central PMCID: 2045570, Epub 2007/08/10. eng.
Schwartz RA, Carson CT, Schuberth C, Weitzman MD. Adeno-associated virus replication induces a DNA damage response coordinated by DNA-dependent protein kinase. J Virol. 2009;83(12):6269–78. PubMed Pubmed Central PMCID: 2687378.
Paulk NK, Loza LM, Finegold MJ, Grompe M. AAV-mediated gene targeting is significantly enhanced by transient inhibition of nonhomologous end joining or the proteasome in vivo. Hum Gene Ther. 2012;23(6):658–65. PubMed Pubmed Central PMCID: 3392621.
Miller DG, Petek LM, Russell DW. Human gene targeting by adeno-associated virus vectors is enhanced by DNA double-strand breaks. Mol Cell Biol. 2003;23(10):3550–7. PubMed Pubmed Central PMCID: 164770.
Porteus MH, Baltimore D. Chimeric nucleases stimulate gene targeting in human cells. Science. 2003;300(5620):763. PubMed Epub 2003/05/06. eng.
Li H, Haurigot V, Doyon Y, Li T, Wong SY, Bhagwat AS, et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature. 2011;475(7355):217–21. PubMed Pubmed Central PMCID: 3152293.
Asuri P, Bartel MA, Vazin T, Jang JH, Wong TB, Schaffer DV. Directed evolution of adeno-associated virus for enhanced gene delivery and gene targeting in human pluripotent stem cells. Mol Ther. 2012;20(2):329–38. PubMed Pubmed Central PMCID: 3277219.
Handel EM, Gellhaus K, Khan K, Bednarski C, Cornu TI, Muller-Lerch F, et al. Versatile and efficient genome editing in human cells by combining zinc-finger nucleases with adeno-associated viral vectors. Hum Gene Ther. 2012;23(3):321–9. PubMed Pubmed Central PMCID: 3300077.
Ellis BL, Hirsch ML, Porter SN, Samulski RJ, Porteus MH. Zinc-finger nuclease-mediated gene correction using single AAV vector transduction and enhancement by Food and Drug Administration-approved drugs. Gene Ther. 2013;20(1):35–42. PubMed Epub 2012/01/20. Eng.
Rahman SH, Bobis-Wozowicz S, Chatterjee D, Gellhaus K, Pars K, Heilbronn R, et al. The nontoxic cell cycle modulator indirubin augments transduction of adeno-associated viral vectors and zinc-finger nuclease-mediated gene targeting. Hum Gene Ther. 2013;24(1):67–77. PubMed Pubmed Central PMCID: 3555098.
Anguela XM, Sharma R, Doyon Y, Miller JC, Li H, Haurigot V, et al. Robust ZFN-mediated genome editing in adult hemophilic mice. Blood. 2013;122(19):3283–7. PubMed Pubmed Central PMCID: 3821724.
Beurdeley M, Bietz F, Li J, Thomas S, Stoddard T, Juillerat A, et al. Compact designer TALENs for efficient genome engineering. Nat Commun. 2013;4:1762. PubMed Pubmed Central PMCID: 3644105.
Esvelt KM, Mali P, Braff JL, Moosburner M, Yaung SJ, Church GM. Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. Nat Methods. 2013;10(11):1116–21. PubMed Pubmed Central PMCID: 3844869.
Hirsch ML, Fagan BM, Dumitru R, Bower JJ, Yadav S, Porteus MH, et al. Viral single-strand DNA induces p53-dependent apoptosis in human embryonic stem cells. PLoS One. 2011;6(11), e27520. PubMed Pubmed Central PMCID: 3219675, Epub 2011/11/25. eng.
Song L, Li X, Jayandharan GR, Wang Y, Aslanidi GV, Ling C, et al. High-efficiency transduction of primary human hematopoietic stem cells and erythroid lineage-restricted expression by optimized AAV6 serotype vectors in vitro and in a murine xenograft model in vivo. PLoS One. 2013;8(3), e58757. PubMed Pubmed Central PMCID: 3597592.
Maina N, Han Z, Li X, Hu Z, Zhong L, Bischof D, et al. Recombinant self-complementary adeno-associated virus serotype vector-mediated hematopoietic stem cell transduction and lineage-restricted, long-term transgene expression in a murine serial bone marrow transplantation model. Hum Gene Ther. 2008;19(4):376–83. PubMed.
Srivastava A. Hematopoietic stem cell transduction by recombinant adeno-associated virus vectors: problems and solutions. Hum Gene Ther. 2005;16(7):792–8. PubMed.
Duan D, Yue Y, Engelhardt JF. Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol Ther. 2001;4(4):383–91. PubMed Epub 2001/10/11. eng.
Hirsch ML, Agbandje-McKenna M, Samulski RJ. Little vector, big gene transduction: fragmented genome reassembly of adeno-associated virus. Mol Ther. 2010;18(1):6–8. PubMed Pubmed Central PMCID: 2839225, Epub 2010/01/06. eng.
Hirsch ML, Li C, Bellon I, Yin C, Chavala S, Pryadkina M, et al. Oversized AAV transduction is mediated via a DNA-PKcs independent, Rad51C-dependent repair pathway. Mol Ther. 2013;13. PubMed.
Lai Y, Yue Y, Duan D. Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb. Mol Ther. 2010;18(1):75–9. PubMed Pubmed Central PMCID: 2839223, Epub 2009/11/12. eng.
Wu Z, Yang H, Colosi P. Effect of genome size on AAV vector packaging. Mol Ther. 2010;18(1):80–6. PubMed Pubmed Central PMCID: 2839202, Epub 2009/11/12. eng.
Halbert CL, Allen JM, Miller AD. Efficient mouse airway transduction following recombination between AAV vectors carrying parts of a larger gene. Nat Biotechnol. 2002;20(7):697–701. PubMed Epub 2002/06/29. eng.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 American Society of Gene and Cell Therapy
About this chapter
Cite this chapter
Mitchell, A.M., Moser, R., Samulski, R.J., Hirsch, M.L. (2016). Stimulation of AAV Gene Editing via DSB Repair. In: Cathomen, T., Hirsch, M., Porteus, M. (eds) Genome Editing. Advances in Experimental Medicine and Biology(). Springer, New York, NY. https://doi.org/10.1007/978-1-4939-3509-3_8
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3509-3_8
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-3507-9
Online ISBN: 978-1-4939-3509-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)